Moderna Edges Pfizer in Study of Five Covid Vaccines

According to the paper published on the website of the Clinical Microbiology and Infection journal, Moderna's COVID-19 vaccine edged Pfizer/BioNTech's jab in effectiveness in a large-scale study of five different immunization shots conducted by Hungarian researchers, reported Bloomberg.

The research reviewed data from more than 3.7 million vaccinated people aged 16 and over in the period from January to June of this year.

The Pfizer/BioNTech jab was administered most frequently, to 1.5 million people, followed by China's Sinopharm vaccine at 895,465, Russia's Sputnik V at 820,560, AstraZeneca at 304,138 and Moderna at 222,892, according to the study.

Moderna's vaccine was 88.7% effective in protecting against infections and 93.6% effective against COVID-related mortality, compared with 83.3% and 90.6%, respectively, for the Pfizer/BioNTech shot.

Sputnik V came in third, showing 85.7% effectiveness against infection and 95.4% against COVID-related death.

AstraZeneca had 71.5% effectiveness against infection and 74.5% against COVID-related death, while Sinopharm had 68.7% effectiveness against infection and 87.8% against death. Both of these also had less than 50% efficacy against infection in people aged 85 and older.